ABSTRACT

Novel male contraceptives have been in development for almost as long as female methods, yet there are no products available on the market. Hormonal approaches tested clinically to date include the use of oral, injectable, implant and transdermal methods. The study of attitudes toward male contraception has been inconsistent and there have been no systematic reviews drawing these data together. We conducted a systematic review of the available evidence for male and female acceptability of novel male contraception. We identified 32 studies and present a narrative synthesis of quantitative data and a thematic synthesis of qualitative data. In novel drug trials, the proportion of male participants willing to use a male contraceptive ranged from 34.0% to as high as 82.3%. In studies regarding hypothetical drugs, male willingness to use ranged from 13.6% to 83.0%. High proportions of women (42.8%–94.0%) reported willingness to use a novel male method in both hypothetical studies and actual drug trials. In qualitative studies, both men and women expressed the desire to share responsibility for contraception. There is consistent interest among both men and women in novel male contraceptive methods and willingness to use them. The systematic review was registered with PROSPERO: CRD42020173281.

摘要

新型男性避孕药的开发时间几乎与女性避孕方法一样长，但市场上还没有可用的产品。迄今为止临床测试的激素方法包括使用口服、注射、植入和透皮方法。对男性避孕态度的研究一直不一致，也没有将这些数据汇总在一起的系统评价。我们对男性和女性对新型男性避孕方法的可接受性的现有证据进行了系统审查。我们确定了 32 项研究，并提出了定量数据的叙述性综合和定性数据的主题综合。在新药试验中，愿意使用男性避孕药的男性参与者比例从 34.0% 到高达 82.3% 不等。在有关假设药物的研究中，男性使用意愿的范围为 13。6% 至 83.0%。高比例的女性 (42.8%–94.0%) 表示愿意在假设研究和实际药物试验中使用新的男性方法。在定性研究中，男性和女性都表达了分担避孕责任的愿望。男性和女性对新型男性避孕方法的兴趣和使用意愿始终如一。系统评价在 PROSPERO 注册：CRD42020173281。